In a phase I/II trial, 47% of patients with relapsed/refractory AML and TP53 abnormalities had a complete response to flotetuzumab with responders demonstrating a significantly higher baseline tumor inflammation score than nonresponders. The gene discussed is TP53; the disease is acute myeloid leukemia.